Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 12/2010

01.08.2010 | Review Article

Triptans for the Management of Migraine

verfasst von: Mollie M. Johnston, MD, Alan M. Rapoport

Erschienen in: Drugs | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

Migraine is a chronic, recurrent, disabling condition that affects millions of people in the US and worldwide. Proper acute care treatment for migraineurs is essential for a full return of function and productivity. Triptans are serotonin (5-HT)1B/1D receptor agonists that are generally effective, well tolerated and safe. Seven triptans are available worldwide, although not all are available in every country, with multiple routes of administration, giving doctors and patients a wide choice. Despite the similarities of the available triptans, pharmacological heterogeneity offers slightly different efficacy profiles. All triptans are superior to placebo in clinical trials, and some, such as rizatriptan 10 mg, eletriptan 40 mg, almotriptan 12.5 mg, and zolmitriptan 2.5 and 5 mg are very similar to each other and to the prototype triptan, sumatriptan 100 mg. These five are known as the fast-acting triptans. Increased dosing can offer increased efficacy but may confer a higher risk of adverse events, which are usually mild to moderate and transient in nature. This paper critically reviews efficacy, safety and tolerability for the different formulations of sumatriptan, zolmitriptan, rizatriptan, naratriptan, almotriptan, eletriptan and frovatriptan.
Literatur
1.
Leonardi M, Steiner TJ, Scher AT, et al. The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF). J Headache Pain 2005 Dec; 6(6): 429–40CrossRefPubMedPubMedCentral
2.
Stewart WF, Wood C, Reed ML, et al. Cumulative lifetime migraine incidence in women and men. Cephalalgia 2008; 28: 1170–8CrossRefPubMed
3.
Burton WN, Landy SH, Downs KE, et al. The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. Mayo Clin Proc 2009; 84(5): 436–45CrossRefPubMedPubMedCentral
4.
Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68: 343–9CrossRefPubMed
5.
Bigal ME, Ferrari M, Silberstein SD, et al. Migraine in the triptan era: lessons from epidemiology, pathophysiology, and clinical science. Headache 2009 Jan 21; 49 Suppl. 1: S21–33CrossRefPubMed
6.
Charles A. Advances in the basic and clinical science of migraine. Ann Neurol 2009 May; 65(5): 491–8CrossRefPubMed
7.
Link AS, Kuris A, Edvinsson L. Treatment of migraine attacks based on the interaction with the trigemino-cerebro-vascular system. J Headache Pain 2008; 9: 5–12CrossRefPubMedPubMedCentral
8.
Olesen J, Burstein R, Ashina M, et al. Origin of pain in migraine: evidence for peripheral sensitization. Lancet Neurol 2009; 8: 679–90CrossRefPubMed
9.
10.
Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT 1B/1D receptor agonists. Arch Neurol 2002; 59: 1084–8CrossRefPubMed
11.
Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358: 1668–75CrossRefPubMed
12.
Hamel E. Serotonin and migraine: biology and clinical implications. Cephalalgia 2007 Nov; 27(11): 1293–300CrossRefPubMed
13.
Bigal ME, Bordini CA, Antoniazzi AL, et al. The triptan formulations: a critical evaluation. Arq Neuropsiquiatr 2003; 61(2-A): 313–20CrossRefPubMed
14.
Pascual J, Mateos V, Roig C, et al. Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability. Headache 2007; 47: 1152–68CrossRefPubMed
15.
Pierce M, Marbury T, O’Neill C, et al. Zelrix: a novel transdermal formulation of sumatriptan. Headache 2009 Jun;49(6): 817–25CrossRefPubMed
16.
Rapoport AM, Tepper SJ, Bigal ME, et al. The triptans formulations: how to match patients and products. CNS Drugs 2003; 17(6): 431–47CrossRefPubMed
17.
Rapoport AM, Winner P. Nasal delivery of antimigraine drugs: clinical rationale and evidence base. Headache 2006; 46 Suppl. 4: S192–201CrossRefPubMed
18.
Peterlin BL, Rapoport A. Clinical pharmacology of the serotonin receptor agonist zolmitriptan. Expert Opin Drug Metab Toxicol 2007; 3(6): 899–911CrossRefPubMed
19.
Torres G. Zolmitriptan offers doctors and patient choices for effective treatment of migraine. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 190–8
20.
Goadsby PJ, Ferrari MD, Olesen J, et al. Eletriptan in acute migraine: a double-blind, placebo controlled comparison to sumatriptan. Neurology 2000; 54: 156–63CrossRefPubMed
21.
22.
Allen C. Rizatriptan: clinical update. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 199–205
23.
McCrory DC, Gray RN. Oral sumatriptan for acute migraine. Cochrane Database Syst Rev 2003; (3): CD002915
24.
Newman LC, Cady RK, Landy S, et al. Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100mg tablets utilizing an early intervention paradigm in patients previously unsatisfied with sumatriptan. Int J Clin Pract 2008 Dec; 62(12): 1889–99CrossRefPubMedPubMedCentral
25.
Chen LC, Ashcroft DM. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine. Headache 2008; 48: 236–47CrossRefPubMed
26.
27.
Goadsby PJ, Massiou H, Pascual J, et al. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand 2007; 115: 34–40CrossRefPubMed
28.
Dowson AJ, Charlesworth BR, Green J, et al. Zolmitriptan nasal spray exhibits good long term safety and tolerability in migraine: results of the INDEX trial. Headache 2005; 45: 17–24CrossRefPubMed
29.
Hedlund C, Rapoport A, Dodick D, et al. Zolmitriptan nasal spray in the acute treatment of cluster headache: a meta-analysis of two studies. Headache 2009; 49: 1315–23CrossRefPubMed
30.
Hargreaves RJ, Lines CR, Rapoport AM, et al. Ten years of rizatriptan: from development to clinical science and future directions. Headache 2009 Feb; 49 Suppl. 1: S3–20CrossRefPubMed
31.
Cady RK, Goldstein J, Silberstein S, et al. Expanding access to triptans: assessment of clinical outcome. Headache 2009; 49(10): 1402–13CrossRefPubMed
32.
Lambert GA. Preclinical neuropharmacology of naratriptan. CNS Drug Rev 2005; 11(3): 289–316CrossRefPubMed
33.
34.
Oldman AD, Smith LA, McQuay HJ, et al. Pharmacological treatments for acute migraine: quantitative systematic review. Pain 2002 Jun; 97(3): 247–57CrossRefPubMed
35.
Pascual J. Almotriptan in triptan naýve patients: new evidence of benefits. Cephalalgia 2008; 28 Suppl. 2: 14–20CrossRefPubMed
36.
Chen LC, Ashcroft DM. Meta analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine. Headache 2007; 47: 1169–77CrossRefPubMed
37.
Dowson AJ, Mathew NT, Pascual J. Review of clinical trials using early acute intervention with oral triptans for migraine management. Int J Clin Pract 2006 Jun; 60(6): 698–706CrossRefPubMed
38.
Mett A, Tfelt-Hansen P. Acute migraine therapy: recent evidence from randomized comparative trials. Curr Opin Neurol 2008; 21: 331–7CrossRefPubMed
39.
Buzzi MG. Pathways to the best fit of triptans for migraine patients. Cephalalgia 2008; 28 Suppl. 2: 21–7CrossRefPubMed
40.
Williams P, Reeder CE. A comparison of the cost effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point. J Manag Care Pharm 2004; 10(3): 259–65PubMed
41.
Von Seggern RL. Almotriptan: a review of pharmacology, clinical efficacy, and tolerability. Am J Manag Care 2002; 8: S74–9
42.
Sandrini G, Färkkilä M, Burgess G, et al., Eletriptan Steering Committee. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Neurology 2002 Oct 22; 59(8): 1210–7CrossRefPubMed
43.
Mathew NT, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review. Headache 2003; 43: 962–74CrossRefPubMed
44.
Mathew NT, Schoenen J, Winner P, et al. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache 2003; 43(3): 214–22CrossRefPubMed
45.
McCormack PL, Keating GM. Eletriptan: a review of its use in the acute treatment of migraine. Drugs 2006; 66(8): 1129–49CrossRefPubMed
46.
Sheftell FD, Bigal ME, Rapoport AM, et al. Tolerability and efficacy are related after triptan use [abstract]. Cephalalgia 2003; 23: 697
47.
Sheftell FD, Ryan R, Pitman V. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double blind placebo controlled study conducted in the United States. Headache 2003; 43: 202–13CrossRefPubMed
48.
Stark P, Dahlof C, Haughie S, et al. Efficacy, safety, and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks. Cephalalgia 2002; 22: 23–32CrossRefPubMed
49.
Rapoport AM, Ryan R, Goldstein G, et al. Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache 2002; 42 Suppl. 2: S74–83CrossRefPubMed
50.
Brandes JL, Smith T, Diamond M, et al. Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine. Headache 2007; 47: 886–94CrossRefPubMed
51.
Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short-and long-term use for treatment of migraine and in comparison with sumatriptan. Headache 2002; 42 Suppl. 2: S93–9CrossRefPubMed
52.
Dodick DW, Martin VT, Smith T, et al. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache 2004; 44 Suppl. 1: s20–30CrossRefPubMed
53.
Tomita M, Suzuki N, Igarashi H, et al. Evidence against strong correlation between chest symptoms and ischemic coronary changes after subcutaneous sumatriptan injection. Intern Med 2002; 41: 622–5CrossRefPubMed
54.
Salonen R. Naratriptan: the gentle triptan. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 228–35
55.
Feleppa M, Apice G, D’Alessio A, et al. Tolerability of acute migraine medications: influence of methods of assessment and relationship with headache attributes. Cephalalgia 2008; 28: 1012–6CrossRefPubMed
56.
Dodick DW, Martin V. Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia 2004; 24: 417–24CrossRefPubMed
57.
Dodick DW, Sandrini G, Williams P. Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs 2007; 21(1): 73–82CrossRefPubMed
Metadaten
Titel
Triptans for the Management of Migraine
verfasst von
Mollie M. Johnston, MD
Alan M. Rapoport
Publikationsdatum
01.08.2010
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 12/2010
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/11537990-000000000-00000

Weitere Artikel der Ausgabe 12/2010

Drugs 12/2010 Zur Ausgabe

Therapy in Practice

Laxative Abuse

Adis Drug Evaluation

Inactivated Split-Virion Seasonal Influenza Vaccine (Fluarix®)

Current Opinion

Drug or Vaccine?

Adis Drug Evaluation

Glatiramer Acetate

Adis Drug Profile

Roflumilast

Adis Drug Profile

Oral Colchicine (Colcrys®)